BridgeBio Pharma Inc vs Zillow Group Inc Class A — how do they compare? BridgeBio Pharma Inc trades at $84.57 (market cap $16.36B), while Zillow Group Inc Class A trades at $32.89 (market cap $7.68B). The key difference: BridgeBio Pharma Inc is far larger — about 2.1× Zillow Group Inc Class A's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| BBIO | ZG | |
|---|---|---|
Market Cap | $16.36B | $7.68B |
Sector | Health | Media |
52-Week High | $90.17 | $86.76 |
52-Week Low | $47.29 | $29.14 |
Enterprise Value | $18.14B | $7.56B |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
Zillow Group (ZG) trades at $34.07, up 0.35% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with 2025 revenue of $2.58B and a return to profitability ($23M net income) after years of losses. However, valuation remains elevated with a P/E of 149, while multiple class action lawsuits create near-term uncertainty. The stock faces resistance at $35 with support at $33.
ZG presents a mixed investment case with strong revenue growth and business model transition offset by legal overhangs and high valuation. The preferred agent model drives monetization improvement, but the stock requires careful risk management given the legal proceedings and technical bearish signals. Upside exists to the $47.56 consensus target if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →